Gibson Christopher sold $123K of RXRX
Gibson Christopher sold 40,000 shares of RECURSION PHARMACEUTICALS, INC. (RXRX) at $3.08 ($0.12M total) on 2026-05-22 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Because the sale is explicitly pre-arranged, it is less likely to reflect new negative information; however, it can still affect short-term sentiment around RXRX.
Market read
Trading relevance is mainly sentiment/positioning rather than a fundamental catalyst.
What to watch
Check whether there are multiple recent insider sales/buys and whether the 10b5-1 plan cadence is accelerating or consistent with prior filings.
Background
The article reports a Form 4 insider transaction: director Gibson Christopher sold RXRX shares on 2026-05-22 under a pre-arranged Rule 10b5-1 plan.
Ticker impact
Recursion Pharmaceuticals director Gibson Christopher sold 40,000 shares in an open-market transaction worth $123,200 under a pre-arranged 10b5-1 plan.
Likely limited immediate price impact; any move would be more about broader RXRX news flow than this Form 4.
The filing is a scheduled 10b5-1 sale with no stated linkage to company events (no earnings, trial, deal, or regulatory action).
Market effects
Minimal; insider 10b5-1 sales are common in biotech and usually don’t reset sector expectations without accompanying operational news.
None indicated; this is a US-listed company insider transaction.
None indicated; no cross-border deal, regulator, or trial update mentioned.
Counterpoint
If RXRX is already under pressure, incremental insider selling headlines can amplify bearish positioning even when the sale is pre-planned.
Key entities
- issuerRecursion Pharmaceuticals, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderGibson Christopher
Director who sold 40,000 RXRX shares for $123,200 under a 10b5-1 plan.
